🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to share details of this meeting and the exciting line up of speakers. Hope to see you there. Please re-post crick.ac.uk/whats-on/5th-c…

Radiation-induced amphiregulin drives tumor metastasis nature Ralph Weichselbaum Andras Piffko Sean Pitroda, M.D. nature.com/articles/s4158…

Australia completely lacks a dedicated training program for clinician scientists. With the vision and support of VMIAL Peter Mac Cancer Centre is extremely proud to announce the first clinician-scientist fellowship. If you meet the eligibility criteria PLEASE APPLY! nature.com/naturecareers/…

CAR-T Fellow post available UCLH. Application deadline 04/06/2025. Working with the fabulous Claire Roddie Maeve O'Reilly Paul Maciocia Mike Northend uclh.nhs.uk/work-with-us/c…

The June issue of Cancer Discovery is now online! The cover features work by Yun Rose Li, Allan Balmain, and colleagues showing tumor promotion, not initiation, is the rate-limiting step for carcinogenesis in mouse models - read that and much more here: aacrjournals.org/cancerdiscover…

Circulating tumor DNA monitoring and blood tumor mutational burden in patients with metastatic solid tumors treated with atezolizumab 👉 buff.ly/aVjT1No 🖊️ Charles Swanton David R. Spigel, MD, FASCO Hanna Tukachinsky Amaya Gascó MD PhD #ctDNA #Metastasis #Atezolizumab

Thrilled to announce I'm moving to the CRUK Manchester Institute to lead the Cancer Origins group! If you're interested in how mutations and exposures drive tumourigenesis—come join the adventure. cruk.manchester.ac.uk/careers/

Brilliant piece on lung cancer in people who have never smoked. bbc.com/future/article…

This is fascinating- what an extraordinary detective story - congratulations

Disappointing that Repotrectinib is unlicensed in 🇬🇧, and hence no application for NICE approval So not available for 🇬🇧 patients, despite the evidence of efficacy May not be great commercial priority, but is of great clinical value to our patients ROS1DERS UK The ROS1ders, Inc.

We're deeply saddened that Dr Prateek Joshi, consultant radiologist at Royal Derby Hospital, and his family were on board the Air India flight which tragically crashed yesterday. Our thoughts are with his family, friends and colleagues, and all those impacted by this tragedy.

Excited to share our new study on how resistance to AKT inhibition is linked to lineage differences within breast cancer 👇🏽biorxiv.org/content/10.110… and also surprisingly/worryingly good AI generated podcast 🎧notebooklm.google.com/notebook/28ebc…

Delighted to share this news on the appointment of Professor Samra Turajlić as the Director of the CRUK Manchester Institute. Samra is an outstanding clinician scientist with a remarkable track record in cancer research. Her leadership will enable the Manchester Institute to continue to grow as

A note that I’m sure is obvious but worth stating that cancer cachexia is not just a human pathological condition: the work of Cancer Research UK Cancer Grand Challenges NIH National Cancer Institute and Cancan is so important to uncover the underlying mechanisms

I’m not “riding my bike” this year ….but still raising funds for the Pan-Mass Challenge Challenge ! Everyone can have an impact to cure cancer Dana-Farber Link: profile.pmc.org/TC0306

🚨 #Lungcancer survival has more than doubled. New real-world data from France shows 3-year survival for lung adenocarcinoma rose from 16.3% (2000) to 38.6% (2020) driven by earlier diagnosis & targeted treatment. This is what progress looks like. But it must reach everyone who

Patrick's learning method was deceptively simple: 1. Reverse-engineer everything obsessively 2. Question every assumption 3. Talk to insiders who built the system 4. Build rapid prototypes from first principles No fancy degrees. Just raw curiosity and relentless execution.

Paris pollution after they added bike lanes and restricted cars

📢New Article published Nature Cancer ! 'Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation' ✒️By Cédric Blanpain and colleagues 🔗nature.com/articles/s4301…